Aberrant Glycosylation Signature in Pancreatic Cancer

描述(申请人提供)：胰腺癌是美国癌症死亡的第四大原因。改善胰腺癌治疗结果的主要障碍之一来自于对疾病的早期诊断的困难，这一目标可以显著提高生存率。蛋白质糖基化异常常与恶性转化有关，已被认为是胰腺癌的一个标志。在这项提案中，我们将首先应用定量蛋白质组学来揭示血浆中与胰腺癌相关的糖基化异常。然后，我们将应用高灵敏的平台技术，在一组病例和对照中定量检测与胰腺癌相关的异常糖基化，并测试使用异常糖基化模式作为胰腺癌识别的分子指纹的假设。 公共卫生相关性：胰腺癌是美国癌症死亡的第四大原因，在疾病可以治愈的早期阶段很难诊断出来。胰腺癌的早期诊断迫切需要生物标志物。胰腺癌相关蛋白糖基化异常可能成为胰腺癌识别的分子标志。

DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer death in the United State. One of the major obstacles for improving the outcome in pancreatic cancer treatment arises from the difficulty in diagnosing the disease at an early stage, a goal that could markedly improve the survival rate. Abnormal glycosylation of proteins is often associated with malignant transformation, and has been recognized as a hallmark of pancreatic cancer. In this proposal, we will first apply quantitative proteomics to reveal dysregulated glycosylations associated with pancreatic cancer in plasma. We will then apply a highly sensitive platform technology to quantitatively detect aberrant glycosylations associated with pancreatic cancer in a cohort of cases and controls, and test the hypothesis of using aberrant glycosylation pattern as a molecular fingerprint for pancreatic cancer recognition. PUBLIC HEALTH RELEVANCE: Pancreatic cancer is the fourth leading cause of cancer death in the United State and it is very difficult to diagnosis at an early stage when the disease is curable. Biomarkers are desperately needed for early diagnosis of pancreatic cancer. Aberrant protein glycosylation associated with pancreatic cancer can potentially serve as a molecular signature for pancreatic cancer recognition.